IL117229A - POLYSUBSTITUTED 1H-PYRAZOLO[3,4-d] PYRIMIDINES AND 7H-PYRROLO[2,3-d] PYRIMIDINES FOR TREATMENT OF NEURONAL AND OTHER CRF RELATED DISORDERS - Google Patents

POLYSUBSTITUTED 1H-PYRAZOLO[3,4-d] PYRIMIDINES AND 7H-PYRROLO[2,3-d] PYRIMIDINES FOR TREATMENT OF NEURONAL AND OTHER CRF RELATED DISORDERS

Info

Publication number
IL117229A
IL117229A IL11722996A IL11722996A IL117229A IL 117229 A IL117229 A IL 117229A IL 11722996 A IL11722996 A IL 11722996A IL 11722996 A IL11722996 A IL 11722996A IL 117229 A IL117229 A IL 117229A
Authority
IL
Israel
Prior art keywords
pyrimidines
polysubstituted
pyrazolo
pyrrolo
neuronal
Prior art date
Application number
IL11722996A
Other languages
English (en)
Other versions
IL117229A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL117229A0 publication Critical patent/IL117229A0/xx
Publication of IL117229A publication Critical patent/IL117229A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11722996A 1995-03-02 1996-02-22 POLYSUBSTITUTED 1H-PYRAZOLO[3,4-d] PYRIMIDINES AND 7H-PYRROLO[2,3-d] PYRIMIDINES FOR TREATMENT OF NEURONAL AND OTHER CRF RELATED DISORDERS IL117229A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39752795A 1995-03-02 1995-03-02

Publications (2)

Publication Number Publication Date
IL117229A0 IL117229A0 (en) 1996-06-18
IL117229A true IL117229A (en) 2003-02-12

Family

ID=23571548

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11722996A IL117229A (en) 1995-03-02 1996-02-22 POLYSUBSTITUTED 1H-PYRAZOLO[3,4-d] PYRIMIDINES AND 7H-PYRROLO[2,3-d] PYRIMIDINES FOR TREATMENT OF NEURONAL AND OTHER CRF RELATED DISORDERS

Country Status (11)

Country Link
EP (1) EP0729758A3 (xx)
JP (1) JPH08259567A (xx)
KR (1) KR960033454A (xx)
CN (1) CN1065535C (xx)
AU (1) AU715380B2 (xx)
CA (1) CA2170700C (xx)
IL (1) IL117229A (xx)
MX (1) MX9600832A (xx)
MY (1) MY140557A (xx)
NZ (1) NZ286103A (xx)
ZA (1) ZA961696B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
ES2191183T3 (es) * 1996-08-06 2003-09-01 Pfizer Derivados 6,6- o 6,7-biciclicos que contienen pirido o pirimido sustituidos.
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
PT896822E (pt) * 1997-08-05 2003-07-31 Pfizer Prod Inc 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PL204628B1 (pl) * 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6159943A (en) * 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
DE60026155T2 (de) 1999-09-30 2006-08-10 Neurogen Corp., Branford Einige alkylendiamin-substituierte heterocyclen
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2398956A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
DE10042092A1 (de) * 2000-08-26 2002-03-07 Dresden Arzneimittel Antikonvulsiv wirkende 2,5-Dihydro-pyrazolo(3,4-d)pyrimidin-4-one und Verfahren zu deren Darstellung
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1450811B1 (en) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CA2471059C (en) 2001-12-20 2011-04-26 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2007502772A (ja) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド ４−シクロアルキルアミノピラゾロピリミジンｎｍｄａ／ｎｒ２ｂ拮抗薬
CN1910190A (zh) 2004-01-06 2007-02-07 大正制药株式会社 环氨基取代的噻吩并嘧啶和噻吩并吡啶衍生物
CA2552503C (en) * 2004-01-06 2011-09-13 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
EP2004656B1 (en) 2006-04-07 2013-07-10 Boehringer Ingelheim International GmbH Thienopyrimidines having mnk1 /mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
US9555032B2 (en) 2007-06-13 2017-01-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
KR20110045019A (ko) 2008-08-26 2011-05-03 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 티에노피리미딘
AU2011219764A1 (en) 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
TW201141872A (en) 2010-02-26 2011-12-01 Boehringer Ingelheim Int Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
JP6082397B2 (ja) 2011-09-30 2017-02-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． マクロ環状ｌｒｒｋ２キナーゼ阻害剤
CN103864653A (zh) * 2012-12-10 2014-06-18 韩冰 一类降低眼压的化合物及其用途
CN103864797A (zh) * 2012-12-10 2014-06-18 韩冰 一类具有神经保护作用的化合物及其用途
PL3194405T3 (pl) 2014-09-17 2019-07-31 Oncodesign S.A. Makrocykliczne inhibitory kinazy lrrk2
MX2019007803A (es) 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
CN117865965B (zh) * 2024-01-08 2024-06-28 贵州省天然产物研究中心 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818676A1 (de) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4213977A (en) * 1978-11-20 1980-07-22 Sterling Drug Inc. Pituitary-adrenal inhibiting method
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
CA2100863A1 (en) * 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US5712303A (en) * 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists

Also Published As

Publication number Publication date
CA2170700A1 (en) 1996-09-03
CA2170700C (en) 1999-07-27
CN1141297A (zh) 1997-01-29
NZ286103A (en) 2000-08-25
EP0729758A2 (en) 1996-09-04
AU4585996A (en) 1996-09-12
AU715380B2 (en) 2000-02-03
KR960033454A (ko) 1996-10-22
IL117229A0 (en) 1996-06-18
CN1065535C (zh) 2001-05-09
EP0729758A3 (en) 1997-10-29
MX9600832A (es) 1997-02-28
ZA961696B (en) 1997-09-01
JPH08259567A (ja) 1996-10-08
MY140557A (en) 2009-12-31

Similar Documents

Publication Publication Date Title
IL117229A (en) POLYSUBSTITUTED 1H-PYRAZOLO[3,4-d] PYRIMIDINES AND 7H-PYRROLO[2,3-d] PYRIMIDINES FOR TREATMENT OF NEURONAL AND OTHER CRF RELATED DISORDERS
EP0813527A4 (en) 6-SUBSTITUTED PYRAZOLO (3,4-D) PYRIMIDIN-4-ONE, PREPARATIONS, METHOD AND USE THEREOF
HUP9902049A3 (en) Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production
PL328776A1 (en) Pyrimido [5,4-d] pyrimidines, therapeutic agents containing such compounds, their application and method of obtaining such compounds
AU9693998A (en) Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
IL113912A (en) Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders
CA2041113A1 (en) Thienobenzodiazepine derivatives and their use as pharmaceuticals
PL322623A1 (en) Derivatives of imidazo [1,2-a] pyridine
AU5501598A (en) Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments
PL322647A1 (en) Application of derivatives of imidazo [1,2-a] pyridino -3- acetamide in treating neuropsychiatric syndroms associated with disorders in functioning of neuronal circuits in the base of the brain
EP0813534A4 (en) 6-ARYL PYRAZOLO 3,4-D] PYRIMIDIN-4-ONES, COMPOSITIONS AND METHODS OF USE THEREOF
PT84478A (en) Pyrazolo ]3,4-d" pyrimidine derivatives their production and use
DE69633503D1 (de) 1,2,4- triazolo (4,3-b) pyridazinderivate und ihre verwendung
DE68925270D1 (de) Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidinderivate und diese enthaltende Arzneimittel
PL327539A1 (en) 2,7-substituted derivatives of octahydropyrrole[1,2-a]-pyrazine
HU9402253D0 (en) Trisubstituter pyrimido [5,4-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for producing them
HU9700708D0 (en) Pyrimido[1,2-a]indole derivatives and process for producing them
AU4859596A (en) Imidazo{1,2-a}pyridines for the treatment of cns and cardiac diseases
AU4517096A (en) The treatment of autoimmune disease using 2-amino purine derivatives
AU3207297A (en) Process for the production of 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo{1,5-a}benzod iazepine
GB9410441D0 (en) Azabicycloakyl derivatives of imidazo (1,5-a) indol-3-one and process for their preparation
DE69514271D1 (de) 5-alkoxy-1,2,4-triazolo[4,3-c]pyrimidin-3(2h)-thionverbindungen und ihre verwendung zur herstellung von 5-alkoxy-1,2,4-triazolo[1,5-c]pyrimidin-2(3h)thion- und 3-hydroxycarbylthio-5-alkoxy-1,2,4-triazolo[4,3-c]pyrimidinverbindungen
ZA957464B (en) Pyrimido[5,4-d]pyrimidines medicaments comprising these compounds their use and processes for the preparation
GB9410456D0 (en) Imidazolylalkyl derivatives of imidazo (1,5-a) and process for their preparati
AU2153092A (en) Spirofurane derivatives and their use in the treatment of neurological disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees